Retatrutide — Investigational Weight Management
| Size | 10MG, 20MG, 30MG |
|---|
Retatrutide is an investigational molecule targeting GIP, GLP-1, and glucagon receptors. It is being studied for weight management and metabolic conditions and is not FDA-approved.
Price range: $75.00 through $145.00
Certificates of Analysis
- Download Retatrutide 10 mg COA (JPG)
- Download Retatrutide 20 mg COA (JPG)
- Download Retatrutide 30 mg COA (JPG)
Retatrutide — Investigational Weight Management
Retatrutide is being developed as a triple hormone receptor agonist, acting at GIP, GLP-1, and glucagon receptors. Clinical research evaluates its potential in obesity and related metabolic conditions. Research results apply to the studied investigational medicine and do not authenticate products offered under the same name.
At a glance
- Primary focus: investigational weight management and metabolic outcomes.
- Mechanism: GIP, GLP-1, and glucagon receptor activity.
- Status: investigational, with safety and efficacy still under evaluation.
Evidence and intended use
Retatrutide is not FDA-approved. FDA states that it cannot be used in compounding under federal law. This draft is an informational catalog entry, not an offer of a consumer weight-loss medication.
Common question
Is retatrutide an approved alternative to tirzepatide?
No. These are different molecules. Retatrutide remains investigational and is not an approved substitute.
Product details
Confirm the exact formulation, strength, package size, and intended use against the supplier label. Refer to the manufacturer documentation for storage and handling information.
| Compound class | Investigational triple receptor agonist peptide |
|---|---|
| Primary focus | Investigational weight management |
| Size | 10MG, 20MG, 30MG |